TY - JOUR
T1 - Trends in adherence to NCCN guidelines for breast conserving therapy in women with Stage I and II breast cancer
T2 - Analysis of the 1998–2008 National Cancer Data Base
AU - Patrick, Jilma L.
AU - Hasse, Michelle E.
AU - Feinglass, Joe
AU - Khan, Seema A.
N1 - Funding Information:
Lynn Sage Cancer Research Foundation (support for Dr Patrick) and the Northwestern University Surgical Outcomes QIP Program (Dr Feinglass).
Publisher Copyright:
© 2017
PY - 2017/12
Y1 - 2017/12
N2 - Objective To examine temporal trends in guideline adherence for breast cancer local therapy, by race/ethnicity, socioeconomic and insurance status. Background Treatment guidelines recommend breast conserving therapy (BCT) for women with small cancers, but have been unevenly applied. A better understanding of time-trends in guideline adherence may point to interventions for correction. Methods Patients with tumors ≤2 cm (n = 1,081,075) were identified from 1123 NCDB hospitals, dividing the interval 1998–2011 into 5 segments. Significant differences in rates of guideline adherence over time for race/ethnicity, quartiles of income, education, and insurance status were identified using Chi-square tests. Random effects logistic regression was used to compute odds ratios (OR) for the likelihood of guideline adherence controlling for sociodemographic and clinical characteristics, hospital type and region. Results Multivariate models revealed disparities in use of BCT for women ≤39 years (OR 0.49, 95% CI 0.48–0.50); for Asians (OR 0.67, 95% CI 0.65–0.69); for women in the lowest education quartile (OR 0.89, 95% CI 0.87–0.91); and for women in rural regions, (OR 0.79 95% CI 0.76–0.81). The largest radiotherapy disparity was for the oldest women (OR 0.37, 95%CI 0.37–0.38), and in rural regions OR 0.67, 95% CI 0.63–0.71. Over time, differences persisted in BCT use (for race, income, education, insurance type); and for endocrine therapy (by race and education). Conclusion There was mixed progress in reducing disparities in guideline adherence. These results are conservative, since the most favorable tumor stages were analyzed in the NCDB, which reflects higher quality of care than non-participating hospitals.
AB - Objective To examine temporal trends in guideline adherence for breast cancer local therapy, by race/ethnicity, socioeconomic and insurance status. Background Treatment guidelines recommend breast conserving therapy (BCT) for women with small cancers, but have been unevenly applied. A better understanding of time-trends in guideline adherence may point to interventions for correction. Methods Patients with tumors ≤2 cm (n = 1,081,075) were identified from 1123 NCDB hospitals, dividing the interval 1998–2011 into 5 segments. Significant differences in rates of guideline adherence over time for race/ethnicity, quartiles of income, education, and insurance status were identified using Chi-square tests. Random effects logistic regression was used to compute odds ratios (OR) for the likelihood of guideline adherence controlling for sociodemographic and clinical characteristics, hospital type and region. Results Multivariate models revealed disparities in use of BCT for women ≤39 years (OR 0.49, 95% CI 0.48–0.50); for Asians (OR 0.67, 95% CI 0.65–0.69); for women in the lowest education quartile (OR 0.89, 95% CI 0.87–0.91); and for women in rural regions, (OR 0.79 95% CI 0.76–0.81). The largest radiotherapy disparity was for the oldest women (OR 0.37, 95%CI 0.37–0.38), and in rural regions OR 0.67, 95% CI 0.63–0.71. Over time, differences persisted in BCT use (for race, income, education, insurance type); and for endocrine therapy (by race and education). Conclusion There was mixed progress in reducing disparities in guideline adherence. These results are conservative, since the most favorable tumor stages were analyzed in the NCDB, which reflects higher quality of care than non-participating hospitals.
KW - Adherence
KW - Breast cancer
KW - Breast conserving therapy
KW - Disparities
KW - National Cancer Data Base
UR - http://www.scopus.com/inward/record.url?scp=85026773198&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026773198&partnerID=8YFLogxK
U2 - 10.1016/j.suronc.2017.07.006
DO - 10.1016/j.suronc.2017.07.006
M3 - Article
C2 - 29113653
AN - SCOPUS:85026773198
SN - 0960-7404
VL - 26
SP - 359
EP - 367
JO - Surgical Oncology
JF - Surgical Oncology
IS - 4
ER -